CN103097406A - 一种聚乙二醇干扰素偶联物 - Google Patents

一种聚乙二醇干扰素偶联物 Download PDF

Info

Publication number
CN103097406A
CN103097406A CN2012800027605A CN201280002760A CN103097406A CN 103097406 A CN103097406 A CN 103097406A CN 2012800027605 A CN2012800027605 A CN 2012800027605A CN 201280002760 A CN201280002760 A CN 201280002760A CN 103097406 A CN103097406 A CN 103097406A
Authority
CN
China
Prior art keywords
interferon
integer
conjugate
activation
recombinant human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2012800027605A
Other languages
English (en)
Other versions
CN103097406B (zh
Inventor
王亚里
吕爱锋
孙长安
王瑞军
李蕴波
房雷
徐刚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Shengdi Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN201280002760.5A priority Critical patent/CN103097406B/zh
Publication of CN103097406A publication Critical patent/CN103097406A/zh
Application granted granted Critical
Publication of CN103097406B publication Critical patent/CN103097406B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33331—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing imide group
    • C08G65/33334—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing imide group acyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明公开了一种聚乙二醇修饰的干扰素偶联物，其制备方法，以及含有治疗有效量的该干扰素偶联物的药物组合物，及其在制备抗病毒、抗肿瘤、免疫调节药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201280002760.5A 2011-06-14 2012-05-23 一种聚乙二醇干扰素偶联物 Expired - Fee Related CN103097406B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201280002760.5A CN103097406B (zh) 2011-06-14 2012-05-23 一种聚乙二醇干扰素偶联物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2011101586331A CN102824646A (zh) 2011-06-14 2011-06-14 一种聚乙二醇干扰素偶联物
CN201110158633.1 2011-06-14
CN201280002760.5A CN103097406B (zh) 2011-06-14 2012-05-23 一种聚乙二醇干扰素偶联物
PCT/CN2012/075935 WO2012171429A1 (zh) 2011-06-14 2012-05-23 一种聚乙二醇干扰素偶联物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410394786.XA Division CN104151421A (zh) 2011-06-14 2012-05-23 一种聚乙二醇干扰素偶联物

Publications (2)

Publication Number Publication Date
CN103097406A true CN103097406A (zh) 2013-05-08
CN103097406B CN103097406B (zh) 2014-07-16

Family

ID=47328091

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2011101586331A Withdrawn CN102824646A (zh) 2011-06-14 2011-06-14 一种聚乙二醇干扰素偶联物
CN201410394786.XA Pending CN104151421A (zh) 2011-06-14 2012-05-23 一种聚乙二醇干扰素偶联物
CN201280002760.5A Expired - Fee Related CN103097406B (zh) 2011-06-14 2012-05-23 一种聚乙二醇干扰素偶联物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN2011101586331A Withdrawn CN102824646A (zh) 2011-06-14 2011-06-14 一种聚乙二醇干扰素偶联物
CN201410394786.XA Pending CN104151421A (zh) 2011-06-14 2012-05-23 一种聚乙二醇干扰素偶联物

Country Status (3)

Country Link
CN (3) CN102824646A (zh)
TW (1) TWI555758B (zh)
WO (1) WO2012171429A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087739A1 (en) * 2003-04-03 2004-10-14 Hanmi Pharm. Co. Ltd. Peg-physiologically active polypeptide homodimer complex having prolonged in vivo half-life and process for the preparation thereof
CN1754889A (zh) * 2004-06-30 2006-04-05 深圳科兴生物工程有限公司 PEG化干扰素α－1b

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
CN100355784C (zh) * 2004-02-12 2007-12-19 江苏恒瑞医药股份有限公司 聚乙二醇修饰α－干扰素1b的制备方法
TW200643029A (en) * 2005-06-09 2006-12-16 Egen Corp Pegylated interferon alpha-1B

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087739A1 (en) * 2003-04-03 2004-10-14 Hanmi Pharm. Co. Ltd. Peg-physiologically active polypeptide homodimer complex having prolonged in vivo half-life and process for the preparation thereof
CN1754889A (zh) * 2004-06-30 2006-04-05 深圳科兴生物工程有限公司 PEG化干扰素α－1b

Also Published As

Publication number Publication date
CN103097406B (zh) 2014-07-16
CN102824646A (zh) 2012-12-19
CN104151421A (zh) 2014-11-19
TWI555758B (zh) 2016-11-01
WO2012171429A1 (zh) 2012-12-20
TW201249874A (en) 2012-12-16

Similar Documents

Publication Publication Date Title
ES2207830T3 (es) Conjugados de polietilenglicol-interferon alfa para la terapia de infecciones.
Wang et al. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications
RU2485134C2 (ru) Интерферон альфа 2в, модифицированный полиэтиленгликолем, получение препарата и его применение
Hu et al. Site-specific in situ growth of an interferon-polymer conjugate that outperforms PEGASYS in cancer therapy
US8454947B1 (en) PEG-interferon lambda 1 conjugates
MX2011007458A (es) Nuevo conjugado estable de polietilenglicol con interferon alfa, representado por un isomero posicional.
CN103923209B (zh) 一种Lambda干扰素突变体及聚乙二醇衍生物
JP2014525939A (ja) ペグインターフェロンλ１複合体
CN101636411B (zh) 聚乙二醇修饰的干扰素α2a及其制备方法和应用
JP5458416B2 (ja) 二本鎖ポリエチレングリコール化成長ホルモン、その製造方法およびその使用
RU2575796C2 (ru) Пегилированный конъюгат варианта рекомбинантного консенсусного интерферона и способ его получения, и применение
WO2005077421A1 (fr) Procede de preparation d'interferon alpha 1b modifie au polyethylene glycol
CN102453089B (zh) 重组集成干扰素变异体聚乙二醇偶联物的制备和应用
CA2516552A1 (en) Polyethylene glycol modified interferon compositions and methods of use thereof
CN103097406A (zh) 一种聚乙二醇干扰素偶联物
NZ583831A (en) Protein-polymer conjugates comprising interferon-alpha
CN105085658A (zh) 一种白细胞介素29突变体及聚乙二醇衍生物
KR100353392B1 (ko) 높은 생체 활성도를 갖는 생체 활성 단백질과 ｐｅｇ의결합체 제조방법
CN103012579A (zh) 一种长效人干扰素及其制备方法
CN103933577B (zh) 重组集成干扰素变异体聚乙二醇偶联物的制备和应用
CN104147596A (zh) 生物药非共价结合聚合物延长治疗浓度的方法及用途
Abolhasani et al. Chemical modification of recombinant human interferon beta-1a using linear and branched mPEGs
EP3782652A1 (en) Pegylation method
JPH03106900A (ja) 糖鎖修飾ヒトインターフェロン集合体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20180507

Address after: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Co-patentee after: SHANGHAI SHENGDI PHARMACEUTICAL Co.,Ltd.

Patentee after: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Address before: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Patentee before: JIANGSU HENGRUI MEDICINE Co.,Ltd.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140716